Cargando…

Rac GTPases in Hematological Malignancies

Emerging evidence suggests that crosstalk between hematologic tumor cells and the tumor microenvironment contributes to leukemia and lymphoma cell migration, survival, and proliferation. The supportive tumor cell-microenvironment interactions and the resulting cellular processes require adaptations...

Descripción completa

Detalles Bibliográficos
Autores principales: Durand-Onaylı, Valerie, Haslauer, Theresa, Härzschel, Andrea, Hartmann, Tanja Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321480/
https://www.ncbi.nlm.nih.gov/pubmed/30558116
http://dx.doi.org/10.3390/ijms19124041
_version_ 1783385452611371008
author Durand-Onaylı, Valerie
Haslauer, Theresa
Härzschel, Andrea
Hartmann, Tanja Nicole
author_facet Durand-Onaylı, Valerie
Haslauer, Theresa
Härzschel, Andrea
Hartmann, Tanja Nicole
author_sort Durand-Onaylı, Valerie
collection PubMed
description Emerging evidence suggests that crosstalk between hematologic tumor cells and the tumor microenvironment contributes to leukemia and lymphoma cell migration, survival, and proliferation. The supportive tumor cell-microenvironment interactions and the resulting cellular processes require adaptations and modulations of the cytoskeleton. The Rac subfamily of the Rho family GTPases includes key regulators of the cytoskeleton, with essential functions in both normal and transformed leukocytes. Rac proteins function downstream of receptor tyrosine kinases, chemokine receptors, and integrins, orchestrating a multitude of signals arising from the microenvironment. As such, it is not surprising that deregulation of Rac expression and activation plays a role in the development and progression of hematological malignancies. In this review, we will give an overview of the specific contribution of the deregulation of Rac GTPases in hematologic malignancies.
format Online
Article
Text
id pubmed-6321480
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63214802019-01-07 Rac GTPases in Hematological Malignancies Durand-Onaylı, Valerie Haslauer, Theresa Härzschel, Andrea Hartmann, Tanja Nicole Int J Mol Sci Review Emerging evidence suggests that crosstalk between hematologic tumor cells and the tumor microenvironment contributes to leukemia and lymphoma cell migration, survival, and proliferation. The supportive tumor cell-microenvironment interactions and the resulting cellular processes require adaptations and modulations of the cytoskeleton. The Rac subfamily of the Rho family GTPases includes key regulators of the cytoskeleton, with essential functions in both normal and transformed leukocytes. Rac proteins function downstream of receptor tyrosine kinases, chemokine receptors, and integrins, orchestrating a multitude of signals arising from the microenvironment. As such, it is not surprising that deregulation of Rac expression and activation plays a role in the development and progression of hematological malignancies. In this review, we will give an overview of the specific contribution of the deregulation of Rac GTPases in hematologic malignancies. MDPI 2018-12-14 /pmc/articles/PMC6321480/ /pubmed/30558116 http://dx.doi.org/10.3390/ijms19124041 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Durand-Onaylı, Valerie
Haslauer, Theresa
Härzschel, Andrea
Hartmann, Tanja Nicole
Rac GTPases in Hematological Malignancies
title Rac GTPases in Hematological Malignancies
title_full Rac GTPases in Hematological Malignancies
title_fullStr Rac GTPases in Hematological Malignancies
title_full_unstemmed Rac GTPases in Hematological Malignancies
title_short Rac GTPases in Hematological Malignancies
title_sort rac gtpases in hematological malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321480/
https://www.ncbi.nlm.nih.gov/pubmed/30558116
http://dx.doi.org/10.3390/ijms19124041
work_keys_str_mv AT durandonaylıvalerie racgtpasesinhematologicalmalignancies
AT haslauertheresa racgtpasesinhematologicalmalignancies
AT harzschelandrea racgtpasesinhematologicalmalignancies
AT hartmanntanjanicole racgtpasesinhematologicalmalignancies